In Q1 FY2026 (ended March 31, 2026), Ironwood Pharmaceuticals reported revenue of $106.5 million, a 158.9% increase year-over-year. Net income was $40.8 million, up 209.1% from the prior year. Operating income surged 349.3% to $72.6 million, and diluted EPS was $0.24, a 204.3% increase. The company had $220.5 million in cash, $199.5 million in long-term debt, and negative equity of $217.1 million.
•Revenue grew 158.9% YoY to $106.5 million.
•Net income rose 209.1% to $40.8 million.
•Diluted EPS increased 204.3% to $0.24.
•Cash stood at $220.5 million with long-term debt of $199.5 million.
Informational summary based on SEC XBRL figures · generated by deepseek-v4-flash. Not investment advice.
Ironwood Pharmaceuticals, Inc., a biotechnology company focuses on the development and commercialization of therapies for gastrointestinal (GI) and rare diseases in the United States and globally.
It sells linaclotide, a guanylate cyclase type-C (GC-C) agonist for the treatment of adults suffering from irritable bowel syndrome with constipation or chronic idiopathic constipation for pediatric patients suffering from functional constipation under the LINZESS and CONSTELLA names. The company is also developing IW-3300, a GC-C agonist for the treatment of visceral pain conditions, including interstitial cystitis/bladder pain syndrome and endometriosis
Apraglutide, a synthetic peptide long-acting analog of glucagon-like peptide-2 for short bowel syndrome patients dependent on parenteral support for acute graft versus host disease. It has strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc. for the development and commercialization of linaclotide. Incorporated in 1998 and headquartered in Boston, Massachusetts, Ironwood Pharmaceuticals was formerly known as Microbia, Inc. before rebranding in April 2008.
Ironwood Pharmaceuticals, Inc. is a biotechnology company focused on developing and commercializing therapies for gastrointestinal (GI) and rare diseases. Its primary marketed product is linaclotide, a guanylate cyclase type-C (GC-C) agonist, sold under the brand names LINZESS and CONSTELLA. Linaclotide is approved for adults with irritable bowel syndrome with constipation (IBS-C) or chronic idiopathic constipation (CIC), and for pediatric patients with functional constipation. The company also has pipeline candidates: IW-3300, a GC-C agonist for visceral pain conditions such as interstitial cystitis/bladder pain syndrome and endometriosis, and apraglutide, a synthetic peptide analog of glucagon-like peptide-2 for short bowel syndrome and acute graft versus host disease.
Where is Ironwood Pharmaceuticals (IRWD) listed and what currency does it trade in?
Ironwood Pharmaceuticals is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol IRWD. Its shares are traded in United States Dollars (USD). The company is headquartered in Boston, Massachusetts, and its primary listing is in the United States, making it accessible to investors through major US brokerage platforms.
What sector and industry does Ironwood Pharmaceuticals (IRWD) belong to?
Ironwood Pharmaceuticals operates in the Healthcare sector, specifically within the Drug Manufacturers - Specialty & Generic industry. This classification reflects its focus on developing and manufacturing specialty pharmaceutical products, particularly for gastrointestinal and rare diseases. As a biotechnology company, it engages in research, development, and commercialization of innovative therapies, distinguishing it from traditional generic drug manufacturers.
Where is Ironwood Pharmaceuticals (IRWD) headquartered and what markets does it serve?
Ironwood Pharmaceuticals is headquartered in Boston, Massachusetts, United States. It was incorporated in 1998 and originally named Microbia, Inc. before rebranding in April 2008. The company serves markets in the United States and globally. Its key product, linaclotide, is commercialized through strategic partnerships with AbbVie Inc., AstraZeneca AB, and Astellas Pharma Inc., enabling distribution across multiple regions.
How does Ironwood Pharmaceuticals (IRWD) generate revenue?
Ironwood Pharmaceuticals generates revenue primarily through the sale of linaclotide, its flagship product marketed as LINZESS and CONSTELLA for gastrointestinal conditions. The company has strategic partnerships with AbbVie, AstraZeneca, and Astellas for the development and commercialization of linaclotide, which likely involve milestone payments, royalties, or profit-sharing arrangements. Additionally, Ironwood invests in its pipeline, including IW-3300 and apraglutide, which may generate future revenue upon approval. The company's business model focuses on specialty pharmaceuticals, targeting niche therapeutic areas with high unmet medical needs.